Coconut oil and animal fats (butter, lard, beef tallow) are both dominated by saturated fatty acids, but they are dominated by different saturated fatty acids, and those molecules behave differently in the body. Coconut oil’s signature fat, lauric acid (12 carbons), is one of the two most powerful HDL-raising saturated fats there is (myristic acid is its close, statistically indistinguishable rival), and in head-to-head trials coconut oil produces a better lipid profile than butter. That difference is real and reproducible. But beating butter, the single worst common fat for cholesterol, is a low bar, and clearing it is where coconut oil’s good news ends. Compared with liquid plant oils like olive, canola, soybean, or sunflower oil, coconut oil substantially raises LDL cholesterol, the single best-established causal driver of atherosclerosis, and the HDL it raises has never been shown to be functional or protective. Every attempt in medical history to buy cardiovascular safety with a higher HDL number has failed.

When you walk the entire hierarchy of evidence from cell biology to genetics to outcome trials, the ranking that emerges is remarkably consistent: liquid plant oils at the top, and coconut oil somewhere in the middle of the saturated pack (better than butter, roughly comparable to or slightly worse than tallow and lard on LDL, depending on the comparison). No version of “swap one solid fat for another” substitutes for the swap that actually reduces heart attacks, which is replacing saturated fat with unsaturated fat, the kind that comes overwhelmingly from plants. That is the destination. The rest of this article is the journey, rung by rung, up the evidence pyramid, including the honest complications, the studies skeptics cite, and where the legitimate uncertainty still lives.

What coconut oil and animal fats are actually made of

Lipid scientists stopped treating saturated fat as one substance decades ago, because saturated fatty acids of different carbon chain lengths interact differently with liver receptors, digestion pathways, and blood lipids. The four that matter most in food are lauric acid (C12), myristic acid (C14), palmitic acid (C16), and stearic acid (C18), and they are not evenly distributed across fats.

What is coconut oil made of?

Approximate fatty-acid profiles, as a percentage of total fat, look like this (figures vary by source and processing):

• Coconut oil: about 82–92% saturated. Lauric acid 45–48%, myristic 16–18%, palmitic 8–9%, stearic about 3%, the true medium-chain fats caprylic and capric (C8–C10) about 13%, monounsaturated fat about 6%, polyunsaturated about 2%.
• Butter: about 63–68% saturated. Palmitic 26–31%, myristic 10–12%, stearic 10–12%, lauric about 3%, monounsaturated about 24%, plus roughly 3% naturally occurring trans fat.
• Beef tallow: about 50–55% saturated. Palmitic 24–26%, stearic 17–19%, and about 40–43% monounsaturated oleic acid.
• Lard: about 39–42% saturated. Palmitic 24–26%, stearic 13–14%, and about 44–47% monounsaturated oleic acid.

Values are compiled from USDA FoodData Central and the fatty-acid tables in the American Heart Association Presidential Advisory [1].

Is coconut oil a medium-chain triglyceride (MCT) oil?

No, and this is the most common myth about it. True MCTs, the caprylic (C8) and capric (C10) acids in commercial MCT oil, are absorbed directly into the portal vein and burned rapidly by the liver, but they make up only about 13% of coconut oil. Lauric acid sits on a biochemical borderline: it is technically classified as medium-chain, yet during human digestion roughly 70–75% of it is packaged into chylomicrons and enters the bloodstream exactly like a long-chain animal fat, with only a minority fraction taking the rapid portal route [2, 28, 33]. Studies of purified C8/C10 MCT oil therefore cannot be extrapolated to coconut oil, which is itself about a quarter myristic-plus-palmitic acid, the same long-chain saturated fats found in butter and beef. The full journey these particles take, from bile to chylomicron to lymph to liver, and why the body routes dietary fat so differently from almost everything else you eat, is the subject of a companion piece, Animal Fat, Plant Fat, and the Journey From Your Plate to Your Arteries.

Is all animal fat the same? Butter vs. beef tallow vs. lard

No. “Animal fat” is not one profile. Butter, a dairy fat, is the myristic-and-palmitic heavyweight, plus roughly 3% naturally occurring trans fats [1]. Beef tallow and lard, by contrast, carry relatively little myristic acid; their saturated fraction is mostly palmitic plus a large share of stearic acid, and stearic acid is the one saturated fat that does not raise LDL cholesterol, a fact established in a classic metabolic study by Bonanome and Grundy in 1988 [24] and confirmed in every pooled analysis since [3, 4]. Tallow and lard are also 40% or more monounsaturated oleic acid, the same fatty acid that dominates olive oil. This is why, gram for gram, butter is generally the worst common fat for LDL, with tallow and lard less bad, though still worse than any liquid plant oil.

Does coconut oil contain any heart-healthy fat?

Barely. Coconut oil has essentially no polyunsaturated fat and almost no monounsaturated fat. Whatever else is true of it, it displaces the fats with the strongest evidence for cardiovascular benefit, the unsaturated fats concentrated in vegetable oils, nuts, seeds, olives, and avocados.

Climbing the evidence pyramid

Good nutrition science is not one kind of study; it is the concordance of many kinds, each with different blind spots. Here is the climb, from cell biology at the bottom to genetics and outcome trials at the top.

How does saturated fat raise LDL cholesterol?

Your liver clears LDL particles from the blood using LDL receptors, molecular vacuum ports on the surface of liver cells. Landmark animal experiments by Spady, Woollett, and Dietschy in the 1980s and 1990s showed that long-chain saturated fatty acids (palmitic and myristic in particular) suppress LDL-receptor activity, so fewer LDL particles get pulled out of circulation, while unsaturated fats and cholesterol depletion up-regulate the receptors [25, 26]. This mechanism was later observed in humans: when men and women reduced saturated fat intake in a controlled feeding study, LDL-receptor abundance on their cells measurably increased, in proportion to the fall in their LDL cholesterol [27]. Receptor down-regulation, not some vague “clogging,” is the core molecular reason saturated fat raises LDL.

Where does lauric acid fit? Its partial medium-chain metabolism and its outsized effect on HDL make it mechanistically distinct, and it is often described as suppressing LDL receptors less aggressively than palmitic acid. That is plausible, but a candid reading of the literature is that the receptor biology of lauric acid specifically is far less studied in humans than that of palmitic acid, and the pooled human-feeding data complicate the tidy story, because per calorie, lauric acid raises LDL at least as much as palmitic acid does. Mechanism proposes; feeding studies dispose.

Does lauric acid raise cholesterol less than other saturated fats?

This is where the coconut debate really lives. Starting with the famous Keys and Hegsted equations of 1965 [17, 18], researchers fed people precisely controlled diets and measured lipid responses. Dozens of these trials were pooled in Mensink and Katan’s meta-analysis of 60 controlled trials (2003) [3] and updated in Mensink’s regression analysis commissioned by the World Health Organization (2016) [4]. Expressed as the effect of replacing 1% of dietary energy from carbohydrate, the per-fatty-acid results run like this:

• Lauric acid (C12): the largest LDL rise of any saturated fatty acid, and among the largest HDL rises of any fatty acid (the WHO’s 2016 regression actually gives myristic acid a very slightly higher point estimate for HDL, 0.021 versus 0.019 mmol/L per 1% of energy, though their confidence intervals overlap so the two are not meaningfully different). Lauric is nonetheless the only saturated fat that improves the total-to-HDL ratio (by about 0.033–0.037), because its LDL rise is smaller relative to its HDL rise than myristic’s is.
• Myristic acid (C14): raises LDL, raises HDL, roughly no change to the ratio.
• Palmitic acid (C16): raises LDL, small HDL rise, roughly no change to the ratio.
• Stearic acid (C18): roughly neutral on LDL, roughly neutral to slightly favorable on the ratio.
• Cis-unsaturated fats (monounsaturated and polyunsaturated): lower LDL and improve the ratio.

Read that carefully, because it contains the two facts that fuel the entire coconut-oil debate, and they point in opposite directions. First: in the pooled regressions, lauric acid was the most potent total- and LDL-cholesterol-raising saturated fatty acid, per calorie [3, 4]. That surprises people, and it directly contradicts a claim you will find in many pro-coconut articles: that lauric acid raises LDL less than palmitic acid gram for gram. The individual head-to-head trials are genuinely mixed. Denke and Grundy’s 1992 comparison found lauric slightly gentler on LDL than palmitic [19], Zock’s trial found myristic acid worse than palmitic [20], and Temme’s lauric-plus-myristic diet landed close to palmitic on LDL [21]. But the best pooled estimate does not support the idea that lauric acid is a weak LDL-raiser. It is not.

Does coconut oil improve your cholesterol ratio?

Here is the second fact: lauric acid raises HDL so much more than it raises LDL that it is the only saturated fatty acid that significantly improves the total-to-HDL cholesterol ratio relative to carbohydrate, by about 0.033 to 0.037 per 1% of energy [3, 4]. Myristic and palmitic acids barely move the ratio. This ratio effect is, as the AHA’s own science commentary acknowledged, the entire basis for the optimistic health claims made about coconut oil [1]. Mensink’s WHO analysis itself, however, cautioned against over-reading it: a favorable shift in the cholesterol ratio produced by a particular fatty acid should not be assumed to translate into lower cardiovascular risk unless outcome studies confirm it, and for lauric acid specifically, they never have [4]. So which fact wins, the LDL rise or the ratio improvement? That question cannot be answered at this rung. It gets answered at the top, by genetics and outcome trials.

One more feeding-study result is worth knowing. In 1985, a beef-industry-funded trial directly compared beef tallow, coconut oil, and safflower oil in the same subjects, and found plasma cholesterol was higher on coconut oil than on beef fat [23]. A decade later, Cox’s New Zealand trial compared coconut oil, butter, and safflower oil and found butter produced the highest LDL, coconut oil intermediate, safflower lowest [22]. Together these two small crossover studies preview the modern ranking: butter worst, coconut oil and tallow trading places in the middle depending on the outcome, unsaturated oil best.

Coconut oil vs. butter vs. olive oil: what the trials show

The single most-discussed modern trial is the BBC-recruited “COB” study led by Kay-Tee Khaw at Cambridge (2018): 96 healthy adults aged 50 to 75 randomized to 50 grams daily of extra-virgin coconut oil, butter, or extra-virgin olive oil for four weeks [5]. Butter raised LDL significantly compared with coconut oil (+0.42 mmol/L, about 16 mg/dL) and compared with olive oil (+0.38), while coconut oil and olive oil did not differ significantly on LDL (a difference of just -0.04). Coconut oil raised HDL versus both butter (+0.18) and olive oil (+0.16), and butter worsened the total-to-HDL ratio versus coconut oil while coconut oil matched olive oil on the ratio [5].

This trial is the strongest card in the pro-coconut hand, and it deserves to be reported honestly: in this one four-week study, coconut oil looked clearly better than butter and, on LDL, statistically indistinguishable from olive oil. It also deserves its caveats. It was a single short trial in healthy older adults, its coconut-versus-olive LDL result is an outlier against the pooled literature, a 2024 secondary analysis of its plasma fatty acids confirmed the expected metabolic signatures of each fat [5], and its own authors wrote that the findings do not change the recommendation to reduce saturated fat overall [5].

Other modern trials fill in the picture. Maki’s 2018 randomized crossover found corn oil significantly lowered LDL and total cholesterol compared with coconut oil [29]. In Kerala, India, coconut country, Vijayakumar randomized about 200 patients with stable coronary disease to coconut oil or sunflower oil as their cooking fat for two years and found no significant differences in lipids or clinical events, a genuinely reassuring null, but from a small study using modest cooking-oil quantities within a mixed diet [30]. Small virgin-coconut-oil (VCO) trials, including Cardoso’s study in Brazilian cardiac patients (higher HDL, smaller waists) [31], Assunção’s in Brazilian women with abdominal obesity, and Harris’s against high-oleic safflower, are frequently cited by coconut marketers; they are short, small, often open-label. A systematic review and meta-analysis of 14 VCO trials totaling 1,049 participants, published in late 2025, concluded the clinical evidence for VCO’s proposed metabolic benefits remains mixed, with interventions lasting only 2 to 24 weeks [32].

What did the big coconut oil meta-analysis find?

The definitive pooling is Neelakantan, Seah, and van Dam’s systematic review and meta-analysis of 16 trials, published in Circulation in 2020 [2]. Compared with nontropical vegetable oils, coconut oil consumption raised total cholesterol by 14.69 mg/dL, LDL cholesterol by 10.47 mg/dL (about 8.6%), and HDL cholesterol by 4.00 mg/dL (about 7.8%), with no significant change in triglycerides. Coconut oil also had no significant effect on body weight, body fat, waist circumference, fasting glucose, or C-reactive protein compared with vegetable oils, quietly demolishing the belly-fat, blood-sugar, and anti-inflammatory claims in one table [2]. Strikingly, coconut oil raised LDL even when compared with palm oil, the other tropical saturated oil [2, 56]. The accompanying editorial by Frank Sacks concluded that coconut oil may be viewed as one of the most deleterious cooking oils for cardiovascular risk, while acknowledging it behaves more favorably than butter [56]. So the biomarker verdict is precise. Against butter, coconut wins. Against liquid plant oils, coconut clearly loses on LDL and “wins” on HDL, and whether that HDL win is worth anything is a question biomarker trials cannot answer.

Does cutting saturated fat actually prevent heart attacks?

Yes. No randomized trial of coconut oil, tallow, or butter specifically has ever been run with heart attacks and strokes as endpoints. What we have are the decades-long saturated-fat-reduction trials, pooled in the 2020 Cochrane review by Hooper and colleagues: roughly 56,000 to 59,000 participants, showing that reducing saturated fat intake cut combined cardiovascular events by 17% (risk ratio 0.83, 95% confidence interval 0.70 to 0.98), with a dose-response, so the more saturated fat and serum cholesterol came down, the fewer the events, although effects on total mortality were small or absent over the trial durations [6]. The number needed to treat was about 56 people reducing saturated fat for four years to prevent one cardiovascular event [6]. The AHA’s separate “core trials” analysis estimated that replacing saturated fat with polyunsaturated vegetable oil reduced cardiovascular disease by roughly 30%, a statin-sized effect [1]. This is the rung that converts “LDL went up 10 mg/dL” from an abstraction into an expectation of harm.

Did coconut-eating populations avoid heart disease?

This is the strongest card the other side holds, so it deserves a fair hearing. Prospective cohort studies broadly agree with the trials, with instructive wrinkles: replacing saturated fat with polyunsaturated fat is associated with substantially lower coronary risk, while replacing it with refined carbohydrate buys nothing [1, 34]. The source of saturated fat matters too, with dairy-derived saturated fat associating more neutrally than meat-derived saturated fat in cohorts like MESA [36], and modeling in the Nurses’ Health Study and Health Professionals cohorts found that swapping butter or margarine for olive oil predicted meaningfully lower cardiovascular risk [38].

Then there are the coconut peoples. Ian Prior’s celebrated “natural experiment” (1981) compared two Polynesian atoll populations: Pukapukans obtained about 34% of their energy from coconut and Tokelauans about 63%, probably the highest saturated-fat intake ever documented in a free-living population [15]. Tokelauans’ serum cholesterol ran 35 to 40 mg/dL higher than Pukapukans’, exactly what the Keys, Hegsted, and Mensink arithmetic predicts, yet the investigators reported that vascular disease appeared uncommon in both groups [15]. Staffan Lindeberg’s studies of Kitava, Papua New Guinea, where coconut is a staple alongside tubers, fruit, and fish, likewise found no apparent stroke or ischemic heart disease [16].

What do these prove? Less than either side wants. These populations ate whole coconut flesh and cream (with its fiber and food matrix, not refined oil), almost no processed food or sugar, abundant fish, and lived intensely active, largely non-obese lives, and event ascertainment on remote atolls in that era was limited. What they legitimately show is that a high-saturated-fat intake from whole coconut does not produce an inevitable epidemic of heart disease within a traditional dietary pattern. Tellingly, when Tokelauans migrated to New Zealand and westernized their diets, their risk profiles deteriorated [15]. They do not show that adding refined coconut oil to a modern Western diet is safe, which is the actual question most readers are asking.

Is LDL cholesterol really the cause of heart disease?

Yes, and this is the tiebreaker for the LDL-up, HDL-up puzzle. The 2017 European Atherosclerosis Society consensus assembled evidence from more than 200 prospective studies, Mendelian randomization studies, and randomized trials, covering over 2 million participants, 20 million person-years, and 150,000 cardiovascular events, demonstrating a consistent, dose-dependent, log-linear relationship between LDL exposure and atherosclerotic disease, in which any mechanism that lowers LDL particle concentration lowers risk proportionally [7]. People born with gene variants that lower LDL have proportionally less heart disease; people born with variants that raise it have more. LDL, more precisely the total count of ApoB-carrying particles, is not a “marker.” It is the payload. Exactly how one of those ApoB particles crosses into the artery wall, binds, oxidizes, and hardens into plaque, the molecular crime scene beneath this entire ranking, is walked through step by step in Cholesterol, From the Ground Up.

Does raising HDL protect your heart?

No, and this is the fact that sinks the coconut argument. In the mirror-image Mendelian randomization study, people genetically endowed with lifelong-higher HDL cholesterol had no reduction in heart attacks [8]. Pharmacology agrees with genetics: niacin raised HDL substantially in the AIM-HIGH and HPS2-THRIVE trials and prevented nothing [10, 11]; the CETP inhibitor torcetrapib raised HDL by about 70% and increased deaths [12]; dalcetrapib and evacetrapib were futile; and anacetrapib’s modest benefit in the 30,000-patient REVEAL trial was fully explained by its LDL and ApoB lowering, not its HDL raising [13, 14]. Every road to cardiovascular protection that ran only through a higher HDL number has been a dead end. This is why the “coconut oil improves the ratio” argument fails at the top of the pyramid even though it is true at the bottom. You cannot manufacture protection by inflating the denominator. The heart attacks track the ApoB particles, and coconut oil raises them.

Does coconut oil’s HDL boost actually do anything?

Since HDL quantity is not causal, the research frontier moved to HDL function.

What is cholesterol efflux capacity?

The leading measure of HDL function is cholesterol efflux capacity (CEC), a laboratory assay of how well a person’s HDL actually pulls cholesterol out of macrophages, the cells that become arterial foam cells. CEC has real credentials: in the Dallas Heart Study, people in the top quartile of efflux capacity had about a 67% lower risk of incident cardiovascular events than the bottom quartile, independent of their HDL cholesterol level [9], a finding replicated in other cohorts [59]. When those results were presented, one of the field’s leading HDL researchers publicly declared the old HDL-cholesterol hypothesis ready for retirement in favor of an HDL-function hypothesis [9].

Does coconut oil improve HDL function?

There is no evidence that it does. No adequately sized human trial has demonstrated that coconut oil improves cholesterol efflux capacity or any other validated measure of HDL function. The claim sometimes made in coconut oil’s favor, that its HDL boost is “functional,” is simply unsupported. The claim sometimes made against it, that the extra HDL is definitely dysfunctional “passive cargo,” is a plausible mechanistic hypothesis that also has not been proven in humans. It is a genuine data gap, and intellectual honesty requires labeling it as one. For contrast, extra-virgin olive oil, the fat coconut oil is usually compared against, has randomized trials showing its polyphenols enhance macrophage cholesterol efflux and improve HDL’s functional quality [57], though even there the literature is mixed, with the recent OLIVAUS trial finding improved HDL lipid composition but no significant change in efflux capacity [58]. If the best-studied oil’s HDL-function evidence is mixed, coconut oil’s is essentially a blank page.

The clinical bottom line does not depend on resolving it. Run the arithmetic from the Circulation meta-analysis: HDL up 4 mg/dL, LDL up 10.5 mg/dL versus vegetable oils [2]. Even in the fantasy scenario where every milligram of that HDL were perfectly functional, no evidence anywhere suggests it could neutralize a 10-point rise in causal, plaque-forming LDL particles, because nothing that merely raises HDL has ever neutralized anything. Meanwhile the LDL side of the ledger requires no speculation at all.

What health organizations say about coconut oil and saturated fat

One of the most under-appreciated facts in this debate is the sheer breadth of independent expert bodies, across countries, specialties, and even ideological orientations toward diet, that have reviewed this evidence and landed in the same place.

• American Heart Association (2017 Presidential Advisory): replace saturated with unsaturated fat (about a 30% event reduction in core trials); because coconut oil raises LDL, a cause of cardiovascular disease, and has no known offsetting effects, the advisory explicitly stated, “we advise against the use of coconut oil.” For people with elevated LDL, it advises 5 to 6% of calories from saturated fat [1].
• AHA 2021 Dietary Guidance and the American College of Cardiology: use liquid plant oils in place of animal fats (butter, lard) and tropical oils (coconut, palm kernel) [46].
• ACC/AHA 2019 Primary Prevention Guideline: replace saturated fat with mono- and polyunsaturated fat within a plant-forward pattern [45].
• National Lipid Association: limit saturated fat to under 7% of calories for adults [45, 46].
• World Health Organization (2023 guideline): reduce saturated fat to 10% of energy or less (a strong recommendation for adults and children), replacing it with polyunsaturated and monounsaturated fats from plant sources [41].
• National Academies (Institute of Medicine), Dietary Reference Intakes: no safe threshold identified; keep saturated fat intake as low as possible within a nutritionally adequate diet [43].
• Dietary Guidelines for Americans, 2025–2030 (released January 7, 2026): retains the long-standing limit of under 10% of calories from saturated fat, even as its new food graphic and lists controversially spotlight butter, whole milk, red meat, and beef tallow, a tension flagged publicly by Harvard nutrition scientists. The scientific arm, the 2025 Dietary Guidelines Advisory Committee, had concluded that substituting butter with plant oils is associated with lower cardiovascular disease risk [44].
• UK Scientific Advisory Committee on Nutrition (2019, 47 systematic reviews): reduce saturated fat to 10% of energy or less; replace with unsaturated fats, for example oils instead of butter [42].
• European Society of Cardiology and European Atherosclerosis Society: LDL is causal; dietary saturated fat should be minimized and replaced with unsaturated fat to lower LDL [7, 47].
• Academy of Nutrition and Dietetics: its 2023 evidence-based practice guideline found moderate-certainty evidence that reducing saturated fat lowers cardiovascular events, prioritizing replacement with polyunsaturated fat, and focusing on total saturated fat rather than any single food source [48, 49].
• American Diabetes Association: saturated fat raises cholesterol and cardiovascular risk; emphasize Mediterranean-style patterns replacing saturated with unsaturated fat [50].
• American Cancer Society (2020 guideline): the healthiest patterns are plant-based and include unsaturated fats; limit red and processed meat [51].
• American Academy of Pediatrics (endorsing NHLBI pediatric guidelines): limit saturated fat to about 8 to 10% of calories from age 2 [52].
• American College of Lifestyle Medicine: the optimal pattern centers on whole, minimally processed plant foods and minimizes red and processed meat, foods high in saturated fat, and ultra-processed foods [53].
• Heart Foundations of Australia, New Zealand, and Canada: reviewed coconut oil specifically and recommend unsaturated cooking oils instead of coconut oil, butter, and other solid fats [42, 46].
• JACC: Advances, “Clinician’s Guide to Trending Cardiovascular Nutritional Controversies” (2026): on the beef-tallow revival, evidence of benefit is lacking and evidence of possible harm is considerable; no data support tallow as healthier than seed oils or tropical oils; each 5% of energy swapped from animal saturated fat to unsaturated fat corresponds to about 10% lower cardiovascular risk [54].
• NutritionFacts.org (Dr. Michael Greger): reviews the same trial literature and concludes coconut oil’s LDL raising is not offset by its HDL bump [55].

Notice what is on this list: the cardiologists, the dietitians, the diabetes and cancer societies, the pediatricians, the lifestyle-medicine and plant-based communities, the U.S. National Academies, the UK’s independent scientific committee, and the WHO, bodies that disagree with each other about plenty, all converging on the same two-part conclusion: limit saturated fat regardless of source, and replace it with unsaturated fat, especially from plants. No major scientific organization anywhere recommends coconut oil, tallow, lard, or butter as a heart-healthy fat. Even the 2025–2030 U.S. Dietary Guidelines, produced amid an administration openly enthusiastic about whole milk and beef tallow, could not bring itself to lift the 10% saturated-fat cap, because the underlying evidence review did not support lifting it [44].

The strongest arguments for saturated fat, examined

A credible article steelmans the other side, so here are the strongest cards in the “saturated fat is fine” deck, and why they change the nuance but not the conclusion.

“The Cochrane review found no mortality benefit”

True. Reducing saturated fat clearly cut cardiovascular events (by 17%) but showed little effect on death rates within trial timeframes [6]. Trials lasting a few years in mixed-risk populations are underpowered for mortality; the event reduction, its dose-response with cholesterol lowering, and the genetics all point the same direction. But it is fair to say the dietary evidence is strongest for preventing heart attacks, not for extending lifespan per se. Some critics press further. Zoë Harcombe, for instance, has argued that in a sensitivity analysis restricted to the trials that actually achieved a measured fall in saturated fat, even the cardiovascular-event benefit loses statistical significance [60]. That is a caveat worth stating plainly, but it does not survive contact with the rest of the pyramid: Cochrane’s pre-specified primary analysis remained significant, the benefit scaled with the degree of cholesterol lowering, and the feeding-trial and genetic evidence converge on the same causal mechanism from entirely independent directions. One underpowered subgroup does not overturn a dose-responsive result echoed at every other rung.

“The food matrix matters, cheese and yogurt aren’t butter”

Also true, and the mainstream has absorbed it. A prominent 2020 JACC review led by Arne Astrup argued that whole-food sources of saturated fat (fermented dairy especially) do not carry the risk their fatty-acid content predicts [40], and cohort data on dairy back this up [36, 37]. The 2023 Academy of Nutrition and Dietetics guideline explicitly weighed this and concluded the evidence still favors reducing total saturated fat rather than exonerating categories [49]. Note that the food-matrix argument helps yogurt and cheese far more than it helps refined coconut oil or rendered tallow, which are stripped fats with no matrix at all.

“PURE and the Polynesian studies show high saturated fat is fine”

The PURE study of 18 countries reported that higher saturated fat intake was associated with lower stroke risk and no increase in heart disease [39], a finding that generated enormous headlines and equally enormous methodological critique, since its low-saturated-fat populations were largely poor, eating white-rice-dominated diets, so “more saturated fat” partly proxied for “less poverty and less refined starch.” The Polynesian data have their own limitations: whole-food coconut, a traditional lifestyle, and limited surveillance on the atolls. These are real observations with real limitations. They demonstrate context-dependence; they do not license adding solid fats to a Western diet.

“The big reviews found no link between saturated fat and heart disease”

Three widely cited meta-analyses of prospective cohorts, Siri-Tarino (2010), Chowdhury (2014), and de Souza (2015), did report neutral associations between saturated fat intake and coronary events [61, 62, 63], and coconut and low-carb advocates cite them constantly. The catch is what these studies did and did not ask: an observational association between “how much saturated fat people ate” and “who had heart attacks” says nothing about what replaced it. When the replacement nutrient is specified, the picture flips. Pooling eleven cohorts, swapping saturated fat for polyunsaturated fat was associated with meaningfully lower coronary risk, while swapping it for refined carbohydrate was not [34]. “Saturated fat is not linked to heart disease in a model that ignores the alternative” and “replacing saturated fat with plant oils lowers risk” are both true, and only the second one is a dietary recommendation.

“Swapping saturated fat for vegetable oil didn’t help in the old trials”

This rests on two recovered-data reanalyses, the Sydney Diet Heart Study and the Minnesota Coronary Experiment, in which replacing saturated fat with linoleic-acid-rich oils lowered cholesterol but did not reduce, and in older Minnesota subjects appeared to worsen, mortality [64, 65]. They are legitimate and sobering data. But both interventions leaned heavily on omega-6 linoleic acid in forms that in that era often carried trans fats, both had high dropout and decades-late data recovery, and both are outweighed by the larger body of substitution trials pooled in Cochrane, where replacing saturated fat with unsaturated fat did cut events [6]. They are a genuine argument against the specific claim that any polyunsaturated swap is automatically protective, not evidence that saturated fat is benign.

“What about insulin, inflammation, and triglycerides?”

Coconut oil’s meta-analyzed effects on glycemia, inflammation, and adiposity versus vegetable oils are null [2], so there is no compensating benefit hiding in those columns. For tallow, the newest clinical review actually tilts the other way, citing evidence of endothelial dysfunction with high-heat tallow cooking, impaired insulin sensitivity, and liver-fat promotion [54].

Where does real uncertainty remain?

Three places, and readers deserve to know them. First, no hard-outcome trial of coconut oil or any single cooking fat exists, so all fat-versus-fat rankings rest on validated surrogates (LDL and ApoB) plus triangulation. Second, the HDL functional effects of coconut oil are unstudied, in either direction. Third, individual responses vary widely, since the same tablespoon moves one person’s LDL far more than another’s, which is an argument for testing rather than guessing.

The verdict, and what to do with it

Stack every rung of the pyramid and the picture is coherent from bottom to top.

Is coconut oil healthier than butter?

On the numbers, yes. Coconut oil beats butter on lower LDL, higher HDL, and a better ratio, in trials and meta-analyses alike [2, 5, 22, 28]. But “healthier than the worst common cooking fat” is not the same as “healthy.” Butter is the benchmark coconut oil clears, and clearing it does not make coconut oil a good choice against the liquid plant oils that outperform both.

Is coconut oil or beef tallow better for you?

The contest is closer and less studied than the coconut-versus-butter one. Tallow and lard have stearic-and-oleic-heavy profiles that make them less LDL-raising than butter, and in the one direct comparison coconut oil raised cholesterol more than beef fat [23]. Calling coconut oil “the healthiest saturated fat” and calling it “as bad as lard” are both defensible readings of different endpoints, which is precisely why the fixation on ranking solid fats against each other misses the point. Neither tallow nor coconut oil has evidence of being a healthy alternative, only a marginally different one [22, 23, 54].

What is the healthiest cooking oil?

Every solid fat in this article, coconut, butter, tallow, and lard, raises LDL and ApoB relative to olive, canola, soybean, sunflower, or corn oil [1, 2, 6, 29, 54], and LDL and ApoB are causally, cumulatively, and dose-dependently linked to atherosclerosis [7]. The swap with proven event reduction is saturated to unsaturated [1, 6, 34]. That is the move; the rest is decoration. If the reflex objection here is that those liquid plant oils are the demonized “seed oils,” that claim gets the same rung-by-rung treatment, and collapses at every level of the hierarchy, in Saturated Fat, Seed Oils, and Heart Disease. In practice: make olive oil (or canola, or another liquid plant oil) the default cooking and dressing fat. Zoom out from the single bottle and the same signal only strengthens, because the eating patterns with the deepest evidence base for heart health, the ones the WHO, the dietitians, and the cancer, cardiology, and lifestyle-medicine bodies converge on, are built predominantly on whole plant foods, with unsaturated plant fats doing the cooking. Coconut oil’s honest place in that picture is an occasional flavor, not a foundation. A tablespoon in a curry within an otherwise unsaturated-fat, whole-food pattern is a rounding error; three tablespoons a day “for health” is a 10 mg/dL LDL experiment on yourself with no demonstrated upside [2].

Should you get an ApoB test?

If you eat meaningful amounts of any of these fats, do not argue about it, measure it. An ApoB test counts your actual atherogenic particle burden and cuts through every HDL-related ambiguity in this article, and a lipid panel 6 to 8 weeks after a dietary change will tell you what your liver thinks of your cooking fat. A low triglyceride-to-HDL ratio is a reasonable sign of metabolic health, but it is not a hall pass for a high ApoB.

The nuance in lipid science is real. Chain length matters; lauric acid genuinely is a different molecule from palmitic acid; coconut oil genuinely is better than butter; stearic acid genuinely is neutral; traditional coconut-eating populations genuinely did thrive. And after all of that nuance is fully honored, the hierarchy of evidence still funnels to a conclusion of almost boring stability, unchanged from the WHO to the AHA to the dietitians to the lifestyle-medicine physicians: the fats that protect hearts pour, and they come, overwhelmingly, from plants.

Keep reading

For readers who want to go deeper into the primary research, NutritionFacts.org maintains a free, ad-free library of evidence reviews on these exact topics, and every organizational report cited below is publicly available. This post is one stop on a tour through the same evidence pyramid, applied to different corners of the dietary-fat debate:

• Animal Fat, Plant Fat, and the Journey From Your Plate to Your Arteries follows a single fatty meal from bile to chylomicron to liver, contrasts the animal and plant “fat kingdoms,” and takes apart the fad-diet “I feel great” illusion that powers every keto and carnivore testimonial.
• Saturated Fat, Seed Oils, and Heart Disease confronts the “seed oils are poison” narrative head-on, and shows why the very liquid plant oils that outrank coconut oil in this article lower heart disease at every level of evidence.
• Cholesterol, From the Ground Up is the molecular crime scene beneath this whole ranking: how an ApoB particle crosses into the artery wall, gets trapped, and builds a plaque, and why your arteries can be silently worsening while you feel your best.

This article is for educational purposes and is not medical advice. Lipid responses to diet vary between individuals; decisions about diet, cholesterol testing, and cardiovascular risk should be made with your own clinician.

References

1. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136:e1–e23. doi:10.1161/CIR.0000000000000510
2. Neelakantan N, Seah JYH, van Dam RM. The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Circulation. 2020;141:803–814. doi:10.1161/CIRCULATIONAHA.119.043052
3. Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146–1155.
4. Mensink RP; World Health Organization. Effects of Saturated Fatty Acids on Serum Lipids and Lipoproteins: A Systematic Review and Regression Analysis. Geneva: WHO; 2016.
5. Khaw KT, Sharp SJ, Finikarides L, et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ Open. 2018;8:e020167. (Secondary fatty-acid analysis: Sowah SA, Koulman A, Sharp SJ, Imamura F, Khaw KT, Forouhi NG. J Lipid Res. 2024;65:100681.)
6. Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020;(8):CD011737.
7. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472.
8. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–580.
9. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–2393.
10. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
11. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
12. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events (ILLUMINATE). N Engl J Med. 2007;357:2109–2122.
13. HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
14. Schmidt AF, Hunt NB, Gordillo-Marañón M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12:5640.
15. Prior IA, Davidson F, Salmond CE, Czochanska Z. Cholesterol, coconuts, and diet on Polynesian atolls: a natural experiment: the Pukapuka and Tokelau island studies. Am J Clin Nutr. 1981;34:1552–1561.
16. Lindeberg S, Nilsson-Ehle P, Terént A, Vessby B, Scherstén B. Cardiovascular risk factors in a Melanesian population apparently free from stroke and ischaemic heart disease: the Kitava study. J Intern Med. 1994;236:331–340.
17. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet: IV. Particular saturated fatty acids in the diet. Metabolism. 1965;14:776–787.
18. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr. 1965;17:281–295.
19. Denke MA, Grundy SM. Comparison of effects of lauric acid and palmitic acid on plasma lipids and lipoproteins. Am J Clin Nutr. 1992;56:895–898.
20. Zock PL, de Vries JH, Katan MB. Impact of myristic acid versus palmitic acid on serum lipid and lipoprotein levels in healthy women and men. Arterioscler Thromb. 1994;14:567–575.
21. Temme EH, Mensink RP, Hornstra G. Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. Am J Clin Nutr. 1996;63:897–903.
22. Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M. Effects of coconut oil, butter, and safflower oil on lipids and lipoproteins in persons with moderately elevated cholesterol levels. J Lipid Res. 1995;36:1787–1795.
23. Reiser R, Probstfield JL, Silvers A, et al. Plasma lipid and lipoprotein response of humans to beef fat, coconut oil and safflower oil. Am J Clin Nutr. 1985;42:190–197.
24. Bonanome A, Grundy SM. Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. N Engl J Med. 1988;318:1244–1248.
25. Spady DK, Dietschy JM. Dietary saturated triacylglycerols suppress hepatic low density lipoprotein receptor activity in the hamster. Proc Natl Acad Sci USA. 1985;82:4526–4530.
26. Woollett LA, Spady DK, Dietschy JM. Saturated and unsaturated fatty acids independently regulate low density lipoprotein receptor activity and production rate. J Lipid Res. 1992;33:77–88.
27. Mustad VA, Etherton TD, Cooper AD, et al. Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women. J Lipid Res. 1997;38:459–468.
28. Eyres L, Eyres MF, Chisholm A, Brown RC. Coconut oil consumption and cardiovascular risk factors in humans. Nutr Rev. 2016;74:267–280.
29. Maki KC, Hasse W, Dicklin MR, et al. Corn oil lowers plasma cholesterol compared with coconut oil in adults with above-desirable levels of cholesterol. J Nutr. 2018;148:1556–1563.
30. Vijayakumar M, Vasudevan DM, Sundaram KR, et al. A randomized study of coconut oil versus sunflower oil on cardiovascular risk factors in patients with stable coronary heart disease. Indian Heart J. 2016;68:498–506.
31. Cardoso DA, Moreira ASB, de Oliveira GMM, Luiz RR, Rosa G. A coconut extra virgin oil-rich diet increases HDL cholesterol and decreases waist circumference and body mass in coronary artery disease patients. Nutr Hosp. 2015;32:2144–2152.
32. The effect of virgin coconut oil (VCO) on cardiovascular disease risk factors: a systematic review and meta-analysis (14 RCTs, 1,049 participants). Diabetol Metab Syndr. 2025. doi:10.1186/s13098-025-02019-6
33. Panth N, Abbott KA, Dias CB, Wynne K, Garg ML. Differential effects of medium- and long-chain saturated fatty acids on blood lipid profile: a systematic review and meta-analysis. Am J Clin Nutr. 2018;108:675–687.
34. Jakobsen MU, O’Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr. 2009;89:1425–1432.
35. Zong G, Li Y, Wanders AJ, et al. Intake of individual saturated fatty acids and risk of coronary heart disease in US men and women: two prospective longitudinal cohort studies. BMJ. 2016;355:i5796.
36. de Oliveira Otto MC, Mozaffarian D, Kromhout D, et al. Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2012;96:397–404.
37. Pimpin L, Wu JHY, Haskelberg H, Del Gobbo L, Mozaffarian D. Is butter back? A systematic review and meta-analysis of butter consumption and risk of cardiovascular disease, diabetes, and total mortality. PLoS One. 2016;11:e0158118.
38. Guasch-Ferré M, Liu G, Li Y, et al. Olive oil consumption and cardiovascular risk in U.S. adults. J Am Coll Cardiol. 2020;75:1729–1739.
39. Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries (PURE). Lancet. 2017;390:2050–2062.
40. Astrup A, Magkos F, Bier DM, et al. Saturated fats and health: a reassessment and proposal for food-based recommendations: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:844–857.
41. World Health Organization. Saturated Fatty Acid and Trans-Fatty Acid Intake for Adults and Children: WHO Guideline. Geneva: WHO; 2023.
42. Scientific Advisory Committee on Nutrition (SACN). Saturated Fats and Health. London: Public Health England; 2019.
43. Institute of Medicine (National Academies). Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academies Press; 2005.
44. U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans, 2025–2030 (released January 7, 2026), and Scientific Report of the 2025 Dietary Guidelines Advisory Committee (December 2024). dietaryguidelines.gov
45. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140:e596–e646.
46. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2021;144:e472–e487.
47. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41:111–188.
48. Vannice G, Rasmussen H. Position of the Academy of Nutrition and Dietetics: dietary fatty acids for healthy adults. J Acad Nutr Diet. 2014;114:136–153.
49. Academy of Nutrition and Dietetics. Saturated fat intake and the prevention and management of cardiovascular disease in adults: an evidence-based nutrition practice guideline. J Acad Nutr Diet. 2023.
50. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42:731–754; and American Diabetes Association, Standards of Care in Diabetes (annual).
51. Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 2020;70:245–271.
52. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (NHLBI; endorsed by the American Academy of Pediatrics). Pediatrics. 2011;128(Suppl 5):S213–S256.
53. American College of Lifestyle Medicine. Updated dietary position statement for the treatment and prevention of chronic disease. lifestylemedicine.org (2025–2026 update).
54. A Clinician’s Guide for Trending Cardiovascular Nutritional Controversies in 2026 (beef tallow, seed oils, dairy fat, sweeteners). JACC: Advances. 2026.
55. Greger M. Coconut Oil and the Boost in HDL “Good” Cholesterol. NutritionFacts.org (video series and transcripts).
56. Sacks FM. Coconut oil and heart health: fact or fiction? Circulation. 2020;141:815–817.
57. Helal O, Berrougui H, Loued S, Khalil A. Extra-virgin olive oil consumption improves the capacity of HDL to mediate cholesterol efflux. Br J Nutr. 2013;109:1844–1852; Hernáez Á, et al. Arterioscler Thromb Vasc Biol. 2014;34:2115–2119.
58. OLIVAUS trial: Extra virgin olive oil improves HDL lipid fraction but not HDL-mediated cholesterol efflux capacity: a double-blind, randomised, controlled, cross-over study. Br J Nutr. 2023.
59. Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507–513.
60. Harcombe Z. Cochrane saturated fat reviews (analysis of Hooper et al. 2020, Reduction in saturated fat intake for cardiovascular disease). zoeharcombe.com; June 2020.
61. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010;91:535–546.
62. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014;160:398–406.
63. de Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015;351:h3978.
64. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013;346:e8707.
65. Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968–73). BMJ. 2016;353:i1246.

Last updated: September 27, 2026, 5:51 PM UTC